|
Hello Immunization Partners,
Please share the following information with providers in your jurisdiction.
On January 16, 2025, the Centers for Disease Control and Prevention (CDC) issued two MMWR articles, Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2025 and Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2025.
Both articles describe changes made in the 2025 immunization schedules for children, adolescents, and adults reflecting updated guidance following the Advisory Committee on Immunization Practices (ACIP) meeting in October of 2024. These changes include new and updated recommendations for COVID-19 vaccines, influenza vaccines, meningococcal serogroup B vaccines, pneumococcal conjugate vaccines (PCV), and respiratory syncytial virus vaccines (RSV). These changes are summarized below.
2025 Child and Adolescent Immunization Schedule Changes:
- The schedule now includes the new Bexsero vaccination schedule.
- ACIP recommends MenB-4C (Bexsero) be administered as a 2-dose series at least six months apart when given to healthy adolescents and young adults aged 16 through 23 years based on shared clinical decision-making for the prevention of serogroup B meningococcal disease.
- ACIP recommends MenB-4C (Bexsero) be administered as a 3-dose series over a six-month time period when given to people aged 10 years and older at increased risk for serogroup B meningococcal disease (i.e., people with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to N. meningitidis isolates; and people at increased risk during an outbreak)
- In addition to previously recommended COVID-19 2024–2025 vaccination:
- ACIP recommends a second dose of 2024–2025 COVID-19 vaccine for people ages 6 months through 64 years who are moderately or severely immunocompromised.
- ACIP recommends additional doses (i.e., 3 or more doses) of 2024–2025 COVID-19 vaccine for people ages 6 months and older who are moderately or severely immunocompromised under shared clinical decision making.
2025 Adult Immunization Schedule Changes:
- The 2025 schedule includes a recommendation lowering the age-based recommendations for pneumococcal vaccination from 65 to 50 years old.
- In addition to previously recommended 2024–2025 COVID-19 vaccination:
- ACIP recommends a second dose of 2024–2025 COVID-19 for adults ages 65 years and older.
- ACIP recommends a second dose of 2024–2025 COVID-19 vaccine for people ages 6 months through 64 years who are moderately or severely immunocompromised.
- People ages 6 months and older who are moderately or severely immunocompromised may receive additional doses (i.e., 3 or more doses) of 2024–2025 COVID-19 vaccine under shared clinical decision making.
Please note these changes to the schedules are not addendums, but reflect recommendations made by the committee following the ACIP meeting held in October of 2024. For detailed information regarding 2025 immunization schedule changes by age and antigen, please visit CDC’s Schedule Changes & Guidance website.
Thank you for all you do!
Your Immunization Outreach and Education Team,
Alyssa, Andrea, Dianne, Heidi, and Sarah
|
